How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Hematopathology Clinical Laboratory Service Market
- By Test Type: Flow Cytometry, Immunohistochemistry (IHC), Cytogenetics, Molecular Diagnostics, Morphology and Histopathology
- By Disease Application: Leukemia, Lymphoma, Myeloma, Myelodysplastic Syndromes, Other Hematologic Disorders
- By End User: Hospital-based Laboratories, Independent Clinical Laboratories, Research Institutes, Reference Laboratories
- By Technology Platform: Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In Situ Hybridization (FISH), Digital Pathology
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Flow Cytometry leads By Test Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 277 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.166 →
- 11 Company Profiles 15 players: SWOT & benchmarking p.174 →
Full report · locked preview
Everything inside the Hematopathology Clinical Laboratory Service Market report
A complete, evidence-based study - 11 chapters and 116 sections covering market size, segmentation across 4 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Test Type 5
Disease Application 5
End User 4
Technology Platform 4
Companies profiled
Quest Diagnostics
LabCorp
Sonic Healthcare
Eurofins Scientific
Mayo Clinic Laboratories
ARUP Laboratories
Bio-Reference Laboratories
Genoptix Medical Laboratory (a Novartis company)
Neogenomics Laboratories
PathGroup
Incyte Diagnostics
Molecular Pathology Laboratory Network (MPLN)
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Quest Diagnostics
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →LabCorp
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Sonic Healthcare
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Eurofins Scientific
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Mayo Clinic Laboratories
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →ARUP Laboratories
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Bio-Reference Laboratories
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Genoptix Medical Laboratory (a Novartis company)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Neogenomics Laboratories
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →PathGroup
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Incyte Diagnostics
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Molecular Pathology Laboratory Network (MPLN)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Integrated Oncology Solutions
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Inform Diagnostics
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →NeoGenomics
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$6,142M by 2033 · 11.2% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Flow Cytometry60.4
- Immunohistochemistry (IHC)6.0
- Cytogenetics10.8
- Molecular Diagnostics8.5
- Morphology and Histopathology14.2
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$867.3M → $2,218M · 12.5%
Europe$604.5M → $1,408M · 11.1%
Asia Pacific$551.9M → $1,267M · 10.9%
Latin America$341.6M → $736.7M · 10.1%
Middle East and Africa$262.8M → $676.8M · 12.6%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →11.152026
11.172027
11.172028
11.182029
11.202030
11.212031
11.222032
11.232033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Quest Diagnostics22.5
- LabCorp15.3
- Sonic Healthcare5.3
- Eurofins Scientific10.3
- Mayo Clinic Laboratories10.5
- ARUP Laboratories8.2
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Test Type28.5%
Disease Application22.4%
End User36.9%
Technology Platform12.2%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America35.2
- Europe22.3
- Asia Pacific20.1
- Latin America11.7
- Middle East and Africa10.7
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Quest Diagnostics | 85 | 93 | 95 | 79 | 88 | 98 | 90 |
| LabCorp | 69 | 73 | 76 | 84 | 91 | 74 | 78 |
| Sonic Healthcare | 75 | 78 | 86 | 69 | 62 | 66 | 73 |
| Eurofins Scientific | 76 | 74 | 58 | 66 | 72 | 77 | 71 |
| Mayo Clinic Laboratories | 63 | 76 | 58 | 69 | 53 | 57 | 63 |
| ARUP Laboratories | 69 | 52 | 58 | 71 | 49 | 58 | 60 |
| Bio-Reference Laboratories | 45 | 54 | 62 | 64 | 40 | 54 | 53 |
| Genoptix Medical Laboratory (a Novartis company) | 41 | 50 | 58 | 40 | 44 | 55 | 48 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Quest Diagnostics
- LabCorp
- Sonic Healthcare
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Quest Diagnostics | ✓ | ✓ | ✓ | ✓ | ◐ | ✓ |
| LabCorp | ◐ | ✓ | ◐ | ✓ | ✓ | ✓ |
| Sonic Healthcare | ✓ | ◐ | ✓ | ◐ | ✓ | ◐ |
| Eurofins Scientific | ◐ | ◐ | ◐ | ✓ | ◐ | ✓ |
| Mayo Clinic Laboratories | ◐ | ✓ | − | ◐ | ◐ | ◐ |
| ARUP Laboratories | ✓ | − | ◐ | ✓ | − | − |
| Bio-Reference Laboratories | − | − | ◐ | ◐ | − | − |
| Genoptix Medical Laboratory (a Novartis company) | − | ◐ | ◐ | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Quest Diagnostics90
2LabCorp78
3Sonic Healthcare73
4Eurofins Scientific71
5Mayo Clinic Laboratories63
6ARUP Laboratories60
7Bio-Reference Laboratories53
8Genoptix Medical Laboratory (a Novartis company)48
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Quest DiagnosticsLabCorp
Challenger2
Strong scale, closing on the leaders.
Sonic HealthcareEurofins Scientific
Contender2
Focused players with pockets of strength.
Mayo Clinic LaboratoriesARUP Laboratories
Niche2
Specialists in a single segment or region.
Bio-Reference LaboratoriesGenoptix Medical Laboratory (a Novartis company)
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Test Type in North America, then scale across Hematopathology Clinical Laboratory Service Market — a $203M beachhead inside a $3.00B market.
Beachhead (SOM)$203Mobtainable near-term
Serviceable (SAM)$1.13Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion90 fit
Flow Cytometry
Best fit — highest urgency & budget in Test Type.
Economic buyer75 fit
Immunohistochemistry (IHC)
Strong fit — clear ROI and a fast path to value.
End user65 fit
Cytogenetics
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Test Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Disease Application & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales46%
Partner / channel27%
Digital / self-serve20%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Test Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Hematopathology Clinical Laboratory Service Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified44%
Sales qualified20%
Evaluation14%
Closed-won6%
$11.4KCAC
$39KLTV
3.4:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Hematopathology Clinical Laboratory Service Market is a durable-growth opportunity — $7.34B by 2033, compounding at 7.8%.
TAM · 2025$4.02Btoday
TAM · 2033$7.34Bforecast
CAGR7.8%2027–2033
Cumulative$49.8Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$7.34BTotal addressable market
SAM$2.74BServiceable available market
SOM$535MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →7.8% CAGR
Demand compounds through 2033, outpacing GDP across Test Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Test Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$7.34BLarge & growingTAM by 2033 at 7.8% CAGR
$2.74BServiceable nowreachable with today’s model
$535MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$5.72BBear5.1% CAGR
$7.34BBase7.8% CAGR
$9.39BBull10.3% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Disease Application optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Hematopathology Clinical Laboratory Service Market — a $5.39B market by 2033. Plan: grow share from 7.8% to 16.5%.
Market size · 2033$5.39Btotal addressable
Market CAGR10.1%2027–2033
Target share16.5%from 7.8% today
Revenue ambition$889Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.8% | 16.5% | On track |
| Revenue | $407M | $889M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Behind |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | On track |
| Gross margin | 35.2% | 41.7% | Behind |
| Customer retention | 87.3% | 93.5% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Test Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Disease Application capability
A defensible second engine — invest in Disease Application to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Test Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Disease Application
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $119M capacity & capability investment
- Greenlight bolt-on M&A in Disease Application
- Authorise North America expansion plan
- Fund R&D program for Test Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossOn track
- Input-cost & supply riskOn track
- Regulatory / policy changeBehind
- Execution & talentAt risk
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Hematopathology Clinical Laboratory Service Market conversation — a $10.7B market you can size, segment and defend in minutes.
Market size · 2033$10.7Btotal opportunity
Growth8.7%CAGR to 2033
Addressable buyers1,217+accounts in scope
Typical ROI4.3×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Test Type
Goal Grow share in Test Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.3×return on cost, year one
< 3 mopayback period
$41K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Quest DiagnosticsLabCorpSonic HealthcareEurofins ScientificMayo Clinic LaboratoriesARUP LaboratoriesBio-Reference LaboratoriesGenoptix Medical Laboratory (a Novartis company)+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Hematopathology Clinical Laboratory Service Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Hematopathology Clinical Laboratory Service Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Hematology Testing Product Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportHematology Slide Stainers Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportHematology Sample Preparation System Market
Market size, share, segmentation and regional forecast.
$3.3B market · 2025 base year
View reportHematology Oncology Diagnostics Market
Market size, share, segmentation and regional forecast.
$2.0B market · 2025 base year
View reportHematology Indications Related Drugs Market
Market size, share, segmentation and regional forecast.
$2.1B market · 2025 base year
View reportHematology Diagnostic Device Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportHematology Controls and Calibrator Market
Market size, share, segmentation and regional forecast.
$5.9B market · 2025 base year
View reportDigital Olfactory technology Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View reportHematology Calibrators Market
Market size, share, segmentation and regional forecast.
$4.9B market · 2025 base year
View reportHematology and Flow Cytometry Analyzers and Reagents Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportHematology and Coagulation Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View reportHematology Analyzer and System Market
Market size, share, segmentation and regional forecast.
$5.3B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.